HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Corey, M. J. Articles by Vessella, R. L. Search for Related Content PubMed PubMed Citation Articles by Corey, M. J. Articles by Vessella, R. L. Social Bookmarking                      What's this?

J Biol Chem, Vol. 275, Issue 17, 12917-12925, April 28, 2000

Mechanistic Studies of the Effects of Anti-factor H Antibodies on Complement-mediated Lysis^*

Michael J. Corey^§, Robert J. Kinders, Cristina M. Poduje^¶, Connie L. Bruce, Halli Rowley, Lisha G. Brown, G. Michael Hass, and Robert L. Vessella

From  Bion Diagnostic Sciences, Redmond, Washington 98052 and the Departments of ^¶ Microbiology and  Urology, University of Washington, Seattle, Washington 98195

We have recently reported that complement factor H, a negative regulator of complement-mediated cytotoxicity, is produced and secreted by most bladder cancers. This observation was exploited in the development of the BTA stat^TM and BTA TRAK^TM diagnostic assays, both of which make use of two factor H-specific monoclonal antibodies in sandwich format. Here we show that both antibodies exert interesting effects on the biochemistry of complement activation in in vitro systems. Antibody X13.2 competes with C3b for association with factor H and strongly inhibits factor H/factor I-mediated cleavage of C3b, thereby evidently inactivating a negative regulator of complement; yet, the antibody strongly inhibits complement-mediated lysis as well. Conversely, antibody X52.1, which does not compete with C3b and has no effect on solution-phase cleavage of C3b, is capable of enhancing complement-mediated lysis of various cell types, including cancer cells, by over 10-fold. Our observations indicate that it is possible to deconvolute the biochemical roles of factor H in complement by means of appropriate inhibitors, a finding with potentially valuable implications for both basic research and cancer therapy.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				V. P. Ferreira, A. P. Herbert, H. G. Hocking, P. N. Barlow, and M. K. Pangburn Critical Role of the C-Terminal Domains of Factor H in Regulating Complement Activation at Cell Surfaces J. Immunol., November 1, 2006; 177(9): 6308 - 6316. [Abstract] [Full Text] [PDF]

				Z.-Z. Cheng, M. J. Corey, M. Parepalo, S. Majno, J. Hellwage, P. F. Zipfel, R. J. Kinders, M. Raitanen, S. Meri, and T. S. Jokiranta Complement Factor H as a Marker for Detection of Bladder Cancer Clin. Chem., May 1, 2005; 51(5): 856 - 863. [Abstract] [Full Text] [PDF]